Influence of Long-Term Amelioration of Anemia and Blood Pressure Control on Left Ventricular Hypertrophy in Hemodialyzed Patients

Publisher Website
Google Scholar
Abstract
The course of left ventricular hypertrophy was investigated in anemic hemodialysis patients treated with recombinant human erythropoietin (r-huEPO). 12 patients, aged 60.8 ± 9.9 years (mean ± SD) were treated for 18.8 ± 2.7 months. Left ventricular size was estimated by echocardiography performed before treatment and at least 12 months after relieving anemia. Patients had signs of left ventricular and/or asymmetric septal hypertrophy when compared with a nonanemic and normotensive control group matched for sex and age. At baseline, hemoglobin (Hb) was 8.6 ± 0.7 g/dl; interventricular septum thickness (IVST) was 1.75 ± 0.34 cm, left ventricular posterior wall thickness (LVPWT) 1.32 ± 0.19 cm, left ventricular muscle mass index (LVMI) 222.7 ± 41 g/m2 and blood pressure (BP) 146.4 ± 10/81.6 ± 6 mm Hg. Hb rose to 11.4 ± 1.2 g/dl (p < 0.001); IVST and LVMI decreased to 1.42 ± 0.35 cm (p < 0.02) and 155.4 ± 25.1 g/m2 (p < 0.001); LVPWT and BP remained unchanged (1.30 ± 0.26 cm and 146.8 ± 16.9/81.2 ± 7.8 mm Hg) at the end of the study. During the observation period, two groups of 5 and 7 patients differed from each other. The group of 5 patients had higher BP values (158.9 ± 9.8/86.5 ± 5.3 vs. 140.0 ± 9.5/79.2 ± 6.8 mm Hg, p < 0.01nd the period with Hb values above 10 g/dl was shorter (14.5 ± 2.4 vs. 17.8 ± 2.4 months, p < 0.05). These 5 patients failed to show a significant decrease in IVST and LVMI. We conclude that long-term amelioration of anemia in hemodialysis patients is able to induce a regression of left ventricular hypertrophy. However, inadequate BP control may compromise this effect in patients treated with r-huEPO.

This publication has 0 references indexed in Scilit: